David Apelian, Eiger BioPharmaceuticals CEO
June 29, 2023 11:03 AM EDTUpdated 04:11 PM
People
R&D

Eiger Bio­Phar­ma­ceu­ti­cals to fo­cus on GLP-1 can­di­date, cut work­force by 25%

Paul Schloesser

Associate Editor

Eiger Bio­Phar­ma­ceu­ti­cals said it’s now fo­cused on de­vel­op­ing a GLP-1 an­tag­o­nist amid a re­view of its busi­ness that in­cludes lay­ing off 25% of its em­ploy­ees …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times